Renalytix to Report First Quarter Fiscal Year 2022 Financial Results on December 7

Rhea-AI Summary

Renalytix plc (NASDAQ: RNLX) announced that it will release its first quarter fiscal year 2022 financial results on December 7, 2021, before market open. A conference call and webcast are scheduled for 8:30 a.m. EST to discuss these results, business strategy, partnerships, and regulatory processes. The company is a leader in bioprognosis for kidney health, with its product KidneyIntelX™ receiving Breakthrough Designation from the FDA, aimed at improving kidney disease management and prognosis.

Positive

• KidneyIntelX™ received Breakthrough Designation from the FDA, indicating strong market potential.
• The upcoming financial report may provide insights into business growth and strategies.

Negative

• None.

NEW YORK and SALT LAKE CITY, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will release first quarter fiscal year 2022 financial results on Tuesday, December 7, 2021, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (EST) / 1:30 p.m. (GMT).

Conference Call Details:
US/Canada Participant Toll-Free Dial-In Number: (833) 614-1551
US/Canada Participant International Dial-In Number: (914) 987-7290
United Kingdom International Dial-In Number: 0800 0288 438
United Kingdom Local Dial-In Number: 0203 1070 289
Conference ID: 2495524

Webcast Registration link:  https://edge.media-server.com/mmc/p/2s8cwr7x

For further information, please contact:

Renalytix plc		www.renalytix.com
James McCullough, CEO		Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker)		Tel: 020 7710 7600
Alex Price / Nicholas Moore
Investec Bank plc (Joint Broker)		Tel: 020 7597 4000
Gary Clarence / Daniel Adams
Walbrook PR Limited	Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Cawthorne		Mob: 07980 541 893 / 07584 391 303
CapComm Partners
Peter DeNardo		Tel: 415-389-6400 or investors@renalytix.com

About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.

FAQ

When will Renalytix release its first quarter fiscal year 2022 financial results?

Renalytix will release its first quarter fiscal year 2022 financial results on December 7, 2021.

What time is the conference call for Renalytix's financial results?

The conference call will be held at 8:30 a.m. EST on December 7, 2021.

What is the significance of the Breakthrough Designation for KidneyIntelX™?

The Breakthrough Designation from the FDA highlights the product's potential to improve kidney disease prognosis and management.

How can investors join the Renalytix conference call?

Investors can join the conference call by dialing the provided toll-free numbers or through the webcast registration link.